FDA Removes Black-Box Warnings From Three Menopause Patches Amid Supply Shortages

Key points

• The FDA approved the removal of black-box warnings from three estradiol transdermal patches on October 30, 2026.
• This action follows the removal of similar warnings from six menopause treatments in February 2026.
• The FDA did not convene an advisory committee for this decision, citing bureaucratic inefficiencies.
• Officials state that estradiol patch market output has doubled in the last 12 months to meet surging demand.
• The FDA is exploring the possibility of making vaginal estrogen products available over the counter.
• Critics argue the lack of public testimony and advisory review undermines patient safety and transparency.

Background

In February 2026, the FDA removed black-box warnings from six menopause hormone therapy (MHT) products, citing updated evidence that the risk-benefit profile for healthy women under 60 differs from older warnings. This decision was part of a broader Trump administration initiative, including an Executive Order signed in October 2026, to improve women's health outcomes. Prior to this, in November 2025, the FDA began engaging companies to submit labeling revisions, with 29 drug companies having submitted proposals by October 2026. The agency has also utilized regulatory flexibilities, such as allowing compounding of estradiol products, to address supply issues.

How outlets are covering it

The FDA and HHS officials, including Secretary Robert F. Kennedy Jr. and Acting Commissioner Kyle Diamantas, framed the decision as a 'major victory' for women's health, emphasizing that the warnings were 'outdated' and that the agency is working to expand supply. They highlighted the doubling of patch production and the potential for over-the-counter vaginal estrogen. In contrast, The Guardian and critics like Reshma Ramachandran of Yale School of Medicine argued that the FDA bypassed advisory committees and failed to provide clear scientific justification, calling the process 'data-free' and 'misleading.' Ramachandran noted that the July 2025 panel included influencers with conflicts of interest and excluded public testimony, including from the lead investigator of the Women’s Health Initiative. Yahoo/Reuters reported the factual changes but noted that HHS did not provide brand names and that the FDA has not designated the patches as in shortage, despite patient reports of stock-outs.

Why it matters

The removal of black-box warnings may increase patient access to menopause hormone therapy, potentially alleviating symptoms like hot flashes and mood swings. However, the lack of transparent scientific justification and advisory input raises concerns about patient safety, particularly for those with histories of hormone-sensitive cancers. The decision also highlights ongoing tensions between regulatory agencies and public health advocates over the balance between access and safety in healthcare.

What to watch

The FDA is expected to continue working with manufacturers to expand supply and may approve labeling changes for additional MHT products. The agency is also exploring the potential for over-the-counter availability of vaginal estrogen products, which would require FDA approval based on evidence of safe consumer use. Patients are encouraged to speak with their healthcare providers if they face difficulties finding their usual products.